A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

This randomized trial evaluated rivaroxaban (10 mg daily) versus antiplatelet therapy in 1,644 patients without anticoagulation indications after transcatheter aortic-valve replacement (TAVR). The rivaroxaban group had higher rates of death/thromboembolic events (9.8 vs. 7.2 per 100 person-years; HR 1.35) and bleeding (4.3 vs. 2.8 per 100 person-years; HR 1.50), leading to early trial termination. Rivaroxaban showed no net clinical benefit over antiplatelet therapy in this population.

This randomized trial evaluated rivaroxaban (10 mg daily) versus antiplatelet therapy in 1,644 patients without anticoagulation indications after transcatheter aortic-valve replacement (TAVR). The rivaroxaban group had higher rates of death/thromboembolic events (9.8 vs. 7.2 per 100 person-years; HR 1.35) and bleeding (4.3 vs. 2.8 per 100 person-years; HR 1.50), leading to early trial termination. Rivaroxaban showed no net clinical benefit over antiplatelet therapy in this population.